WSCM
TVRD

Wellington Shields Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Wellington Shields Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,015
Closed -$2.36M – 298
2021
Q1 		$2.36M Buy
+3,015
New +$2.06M 0.22% 94

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Shields Capital Management's TVRD Position: Q2 2021 in Review

Wellington Shields Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 3,015 shares — an estimated $2.36M sold.

Wellington Shields Capital Management first reported a position in TVRD in Q1 2021 and held it in 1 quarter. The position peaked at $2.36M in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Wellington Shields Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wellington Shields Capital Management sold 3,015 Tvardi Therapeutics shares in Q2 2021, an estimated $2.36M.
  • Wellington Shields Capital Management first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 1 quarter.
  • Wellington Shields Capital Management's Tvardi Therapeutics position peaked at $2.36M in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Wellington Shields Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.